To include your compound in the COVID-19 Resource Center, submit it here.

Levicept: Modulating NGF

Levicept hopes NGF modulator may be disease modifying in osteoarthritis

Levicept Ltd.'s p75NTR-Fc could provide the analgesic effect of nerve growth factor inhibitors to treat pain in osteoarthritis without the side effects that have sidelined the class in recent years. This potential made Levicept the first company to graduate from Index Ventures' seed-stage incubator, the Index Nursery, and the company is now raising a series A round.

Pfizer Inc. initially developed p75NTR-Fc; however, the pharma shelved the program when it shuttered its Sandwich, U.K., R&D facility

Read the full 751 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE